SynthesisTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2021
The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review.
Synthesis in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Systematic reviews of convalescent plasma in COVID-19 continue to be poorly conducted and reported: a systematic review.Journal of clinical epidemiology · 2022Pooled it
- Thrombotic risk in children with COVID-19 infection: A systematic review of the literature.Thrombosis research · 2021Pooled it
- Clinical effectiveness of convalescent plasma in hospitalized patients with COVID-19: a systematic review and meta-analysis.Therapeutic advances in respiratory diseasePooled it
- Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children.JCI insight · 2022Trial
- The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness.Frontiers in immunology · 2024Review
- Use of COVID-19 Convalescent Plasma for Treatment of Symptomatic SARS-CoV-2 Infection at a Children's Hospital: A Contribution to a Still Inadequate Body of Evidence.Children (Basel, Switzerland) · 2023Article
- COVID-19 in patients with B cell immune deficiency.Journal of immunological methods · 2022Article
- Multisystem Inflammatory Syndrome in Children.The western journal of emergency medicine · 2022Review
- Therapeutic Strategies for COVID-19 Lung Disease in Children.Frontiers in pediatrics · 2022Review
- COVID-19 in Children and Adolescents: Characteristics and Specificities in Immunocompetent and Oncohematological Patients.Mediterranean journal of hematology and infectious diseases · 2022Review
- Convalescent plasma therapy in obese severe COVID-19 adolescents: Two cases report.Annals of medicine and surgery (2012) · 2021Article
- Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews.Diagnostics (Basel, Switzerland) · 2021Review
- The Three Pillars of COVID-19 Convalescent Plasma Therapy.Life (Basel, Switzerland) · 2021Review
- Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series.Life (Basel, Switzerland) · 2021Article
- Coronavirus Disease 2019 in Children.Frontiers in pediatrics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19), a severe illness leading to pneumonia, multiorgan failure, and death. With this study, we performed a systematic review of the literature and ongoing clinical trials on convalescent plasma therapy in pediatric patients with COVID-19. The electronic databases Medline PubMed, Scopus, and Web Of Science were searched. Also, clinical trials registries were searched for potentially eligible studies. A total of 90 records were retrieved after duplicate removal. Eight studies were case reports of children treated with convalescent plasma therapy (14 children, age range, 9 weeks to 18 years); 5 children had a chronic disease. During the hospital stay, 5 received drugs (e.g., remdesivir) in addition to convalescent plasma therapy. No convalescent plasma therapy-related adverse events were reported in 5 studies and 3 made no mention of adverse events. Seven studies concluded that convalescent plasma therapy is or could be a useful therapeutic option; one study made no claims. Only 3 of the 13 retrieved trials underway were planned exclusively for children. This is the first systematic review of the literature regarding convalescent plasma therapy for COVID-19 in children. We found insufficient clinical information on the safety and efficacy of convalescent plasma therapy in children. Nevertheless, the positive outcomes of the few case reports published to date suggest that convalescent plasma therapy may be of potential benefit. Further research with well-designed and powered clinical trials is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.